Stark, Wiebke

[["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Hummel, H. M."],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T10:08:46Z"],["dc.date.available","2018-11-07T10:08:46Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Bayer Vital; Biogen Idec; Novartis; Biogen"],["dc.format.extent","99"],["dc.identifier.isi","000383267201025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39532"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Fingolimod in active pediatric onset multiple sclerosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","119"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","122"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:48:07Z"],["dc.date.available","2017-09-07T11:48:07Z"],["dc.date.issued","2008"],["dc.description.abstract","Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system and the most common disabling neurological disease in young adults. An estimated 5% of MS patients already have first clinical symptoms before the age of 16 years (paediatric MS). In the paediatric age group comprehensive analysis of the natural clinical course and the course under treatment in a large MS cohort is still missing. We describe a cohort of paediatric MS patients treated in the German Centre for Multiple Sclerosis in Childhood and Adolescence. A total of 166 patients with definite MS who are registered in our database were analysed. The observation time was up to 14.9 years with a mean follow-up of 4.1 years. Median age was 12.4 years (range 4 to 18 years). Prior to puberty the gender ratio was almost equal, while in adolescence there was a strong female predominance as is seen in adult onset MS. Almost all patients presented with relapsing-remitting MS. The course of the disease was more benign than in adult MS with a very slow EDSS increase and complete remission after most relapses. Most patients received immunomodulative treatment with interferon-beta or glatiramer acetate and, in severe cases, natalizumab. However, adequate treatment guidelines for this age group are still lacking."],["dc.identifier.doi","10.1007/s00415-008-6022-x"],["dc.identifier.gro","3143202"],["dc.identifier.isi","000263166600021"],["dc.identifier.pmid","19300972"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/690"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Paediatric multiple sclerosis: The experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","MULTIPLE SCLEROSIS"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Stark, W."],["dc.contributor.author","van Rossum, D."],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Bickeboeller, Heike"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T10:58:20Z"],["dc.date.available","2018-11-07T10:58:20Z"],["dc.date.issued","2007"],["dc.format.extent","S200"],["dc.identifier.isi","000251423400617"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50455"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS"],["dc.relation.eventlocation","Prague, CZECH REPUBLIC"],["dc.relation.issn","1352-4585"],["dc.title","Influence of gene polymorphisms on MS susceptibility and clinical presentation in childhood multiple sclerosis patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0194873"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Wuerfel, Eva"],["dc.contributor.author","Weddige, Almuth"],["dc.contributor.author","Hagmayer, York"],["dc.contributor.author","Jacob, Rebecca"],["dc.contributor.author","Wedekind, Lisa"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2019-07-09T11:45:26Z"],["dc.date.available","2019-07-09T11:45:26Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: A number of studies have investigated cognitive impairment in paediatric patients with multiple sclerosis (MS) but deficits regarding executive functions have not been comprehensively assessed up to now. This study was meant to explore cognitive impairment in German paediatric MS patients with a focus on deficits in executive functions and relate these to clinical disease parameters. METHODS AND FINDINGS: Forty paediatric MS patients, which presented at the German centre for MS in childhood and adolescence, were assessed for cognitive deficits applying a very comprehensive battery of cognitive tests including the Wechsler Intelligence scale and subtests of the D-KEFS for executive functions. The performance of MS patients was compared with a group of age and sex matched healthy controls using between-subjects ANOVAs. Paediatric MS patients performed worse in tests assessing verbal comprehension and fluency, processing speed, memory, calculation skills and other executive functions. Arranged by the cognitive domain, group differences were most pronounced regarding verbal comprehension and fluency for the WISC subtests Comprehension (p = 0.000), Vocabulary (p = 0.003) and Information (p = 0.005); regarding processing speed for the written SDMT (p = 0.001) and the WISC subtest Coding (p = 0.005); regarding memory for the VLMT training (p = 0.007) and the BASIC MLT pattern learning training (p = 0.009); regarding executive functions including working memory for the WISC subtest Arithmetics (p = 0.002), the D-KEFS Design Fluency (p = 0.003) and the Corsi block tapping backward task (p = 0.003). Fluid reasoning was largely intact. Relations of cognitive performance and clinical parameters were assessed in MS patients. Disease duration was associated with a reduced performance in tests belonging to the domains verbal comprehension and fluency (WISC Vocabulary: p = 0.034, WISC Information: p = 0.015) and fluid reasoning (WISC Picture Completion: p = 0.003) as well as the WISC Working Memory Index (p = 0.047). Patients with a disease onset between 11 and 14 years performed better in fluid reasoning (WISC matrix reasoning: p = 0.024) than patients with a disease onset at an age above 14. The number of relapses negatively influenced the visual spatial memory performance (BASIC MLT pattern learning training: p = 0.009). CONCLUSIONS: The distribution of cognitive deficits in a representative group German of paediatric MS patients was similar to the pattern known from other European and North-American cohorts. Paediatric MS patients do have cognitive deficits in executive functions and key qualities necessary for successful school performance. Disease duration, age of onset and the number of relapses influence cognitive performance. Cognitive screenings should be implemented on a regular basis for paediatric MS patients, enabling early intervention."],["dc.identifier.doi","10.1371/journal.pone.0194873"],["dc.identifier.pmid","29566099"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15205"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59228"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","32"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","DNP - Der Neurologe und Psychiater"],["dc.bibliographiccitation.lastpage","40"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Schiller, Stina"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-11-28T09:52:30Z"],["dc.date.available","2017-11-28T09:52:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Die Multiple Sklerose gehört zu den häufigsten neurologischen Erkrankungen des jungen Erwachsenenalters. Bis zu 5 % der Patienten erkranken jedoch bereits vor ihrem 16. Lebensjahr. Ätiologie und Pathogenese entsprechen mit hoher Wahrscheinlichkeit der adulten Form, dennoch stellt die pädiatrische MS aufgrund des frühen Erkrankungsbeginns für Patienten, Angehörige und Ärzte eine Herausforderung dar."],["dc.identifier.doi","10.1007/s15202-016-1061-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/10572"],["dc.language.iso","de"],["dc.notes.status","final"],["dc.relation.eissn","2196-6427"],["dc.relation.issn","1616-2455"],["dc.title","Was bei der pädiatrischen multiplen Sklerose zu beachten ist"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1740"],["dc.bibliographiccitation.issue","75"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","1744"],["dc.contributor.author","Huppke, P."],["dc.contributor.author","Blüthner, Rosa M."],["dc.contributor.author","Bauer, O."],["dc.contributor.author","Stark, W,"],["dc.contributor.author","Reinhardt, K."],["dc.contributor.author","Huppke, B."],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2019-07-10T08:13:35Z"],["dc.date.available","2019-07-10T08:13:35Z"],["dc.date.issued","2010"],["dc.description.abstract","Objective: Neuromyelitis optica (NMO) is currently considered a severe relapsing CNS demyelinating disorder that is associated with aquaporin-4 immunoglobulin G (NMO-IgG) while in earlier reports of NMO in childhood it has been described as a benign and monophasic disorder. This study was performed to analyze the prevalence and the clinical course of NMO in a European pediatric cohort of patients with demyelinating CNS disorders. Methods: A cohort study was performed evaluating 118 pediatric patients presenting at the Center for Multiple Sclerosis in Childhood and Adolescents, Go¨ttingen, Germany, with demyelinating CNS disorders between 2000 and 2009. In all patients, NMO-IgG status was determined. Results: The majority of patients (94%) were diagnosed with remitting recurrent multiple sclerosis. Six patients fulfilled the clinical criteria for NMO but only 1 was seropositive for NMO-IgG. This patient had a severe relapsing course in contrast to the seronegative patients who showed a mild and in the majority of cases monophasic course. Conclusions: The diagnostic criteria clearly distinguished the patients with NMO from patients with other demyelinating CNS disorders. In the European pediatric population, NMO is very rare and in the majority of patients not associated with NMO-IgG. These seronegative cases have a benign and predominantly monophasic course and therefore do not need the immunosuppressant therapy that is recommended for NMO in the recent literature."],["dc.identifier.fs","576516"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6319"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61280"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Neuromyelitis optica and NMO-IgG in European pediatric patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Monatsschrift Kinderheilkunde"],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gärtner, J."],["dc.date.accessioned","2019-07-09T11:50:42Z"],["dc.date.available","2019-07-09T11:50:42Z"],["dc.date.issued","2019"],["dc.description.abstract","Die Diagnose einer multiplen Sklerose (MS) wird im Kindes- und Jugendalter anhand der McDonald-Kriterien gestellt. In diese gehen die klinische Präsentation mit schubhaften neurologischen Ausfällen, Anzahl und Verteilung entzündlich-demyelinisierender Läsionen im Zentralnervensystem (ZNS), die mithilfe der Magnetresonanztomographie (MRT) dargestellt werden, sowie Liquorparameter ein. Zur Behandlung eines akuten Schubs hat sich hochdosiertes Methylprednisolon etabliert. Mit einer früh beginnenden verlaufsmodifizierenden Therapie kann die Prognose der MS verbessert werden. Bei Kindern und Jugendlichen mit milder/moderater MS-Verlaufsform wird eine Therapie mit Interferon-β oder Glatirameracetat, für (hoch-)aktive Verlaufsformen eine Therapie mit Fingolimod oder Natalizumab empfohlen. Durch die in den letzten 10 Jahren rasante Entwicklung neuer hochwirksamer monoklonaler Antikörper und oraler Medikamente für adulte MS-Patienten haben sich die Therapieoptionen auch für die MS im Kindes- und Jugendalter deutlich erweitert. Die Therapieentscheidung sollte auf dem klinischen und radiologischen Phänotyp basieren. Für das Therapieansprechen und -Monitoring sind regelmäßige klinische und MRT-Verlaufskontrollen sowie die Kenntnis der Nebenwirkungen von entscheidender Bedeutung."],["dc.identifier.doi","10.1007/s00112-019-0655-y"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15980"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59811"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Aktuelle Therapieempfehlungen bei multipler Sklerose im Kindes- und Jugendalter"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","67"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Monatsschrift Kinderheilkunde"],["dc.bibliographiccitation.lastpage","77"],["dc.bibliographiccitation.volume","157"],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T08:35:09Z"],["dc.date.available","2018-11-07T08:35:09Z"],["dc.date.issued","2009"],["dc.description.abstract","Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system of unknown etiology normally affecting young adults. Approximately 3-5% of MS patients have onset before the age of 16 (pediatric MS). Neurological deficiencies can occur in multifocal localisations. McDonald's criteria include the dissemination in space and time of the disease activity. Symptoms include, for example, visual dysfunction and sensory or motor impairments. The most frequent clinical manifestation in the pediatric group is a relapsing-remitting disease course, with a milder course of disease and a lower rate of progression when compared to adult MS. Typical diagnostic findings are periventricular lesions of the white matter, oligoclonal bands in the cerebrospinal fluid and delayed evoked potentials. Relapses are treated with high-dose methylprednisolone. Prophylactic, immunomodulative therapies as suggested for adult MS patients are also used for children."],["dc.identifier.doi","10.1007/s00112-008-1915-4"],["dc.identifier.isi","000262677700014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17992"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0026-9298"],["dc.title","Pediatric multiple sclerosis (encephalomyelitis disseminata)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S163"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","MULTIPLE SCLEROSIS"],["dc.bibliographiccitation.lastpage","S164"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Neuhaus, A."],["dc.contributor.author","Dreha-Kulaczewski, S. F."],["dc.contributor.author","Strobl, R."],["dc.contributor.author","Merkle, K."],["dc.contributor.author","Stark, W."],["dc.contributor.author","Sailer, M."],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Daumer, M."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T11:25:14Z"],["dc.date.available","2018-11-07T11:25:14Z"],["dc.date.issued","2009"],["dc.identifier.isi","000269652500487"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56582"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1352-4585"],["dc.title","Steps towards a German register in childhood multiple sclerosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e749"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurology - Neuroimmunology Neuroinflammation"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Reinert, Marie-Christine"],["dc.contributor.author","Benkert, Pascal"],["dc.contributor.author","Wuerfel, Jens"],["dc.contributor.author","Michalak, Zuzanna"],["dc.contributor.author","Ruberte, Esther"],["dc.contributor.author","Barro, Christian"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Kropshofer, Harald"],["dc.contributor.author","Tomic, Davorka"],["dc.contributor.author","Leppert, David"],["dc.contributor.author","Kuhle, Jens"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2021-04-14T08:25:14Z"],["dc.date.available","2021-04-14T08:25:14Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1212/NXI.0000000000000749"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17477"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81564"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2332-7812"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]